{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:23:46Z","timestamp":1783376626812,"version":"3.54.6"},"reference-count":117,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.neulet.2013.06.057","type":"journal-article","created":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T16:38:56Z","timestamp":1372869536000},"page":"27-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"PA","title":["Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides"],"prefix":"10.1016","volume":"557","author":[{"given":"Polina","family":"Feldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2013.06.057_bib0005","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1124\/jpet.110.166363","article-title":"Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker","volume":"334","author":"Abbadie","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neulet.2013.06.057_bib0010","first-page":"89","article-title":"Comparative study of clinical efficacy of amitriptyline and pregabalin in postherpetic neuralgia","volume":"20","author":"Achar","year":"2012","journal-title":"Acta Dermatovenerol. Croatica"},{"key":"10.1016\/j.neulet.2013.06.057_bib0015","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/01.BRS.0000048464.57011.00","article-title":"Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms","volume":"28","author":"Ahn","year":"2003","journal-title":"Spine"},{"key":"10.1016\/j.neulet.2013.06.057_bib0020","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.4155\/fmc.12.76","article-title":"Peptides and peptide conjugates: therapeutics on the upward path","volume":"4","author":"Ahrens","year":"2012","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neulet.2013.06.057_bib0025","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.4155\/fmc.12.94","article-title":"Therapeutic peptides","volume":"4","author":"Albericio","year":"2012","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neulet.2013.06.057_bib0030","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pain.2011.10.002","article-title":"Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice","volume":"153","author":"Alicino","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.neulet.2013.06.057_bib0035","doi-asserted-by":"crossref","first-page":"7602","DOI":"10.1523\/JNEUROSCI.5727-11.2012","article-title":"The role of a voltage-dependent Ca2+ channel intracellular linker: a structure\u2013function analysis","volume":"32","author":"Almagor","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2013.06.057_bib0040","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1523\/JNEUROSCI.0307-07.2007","article-title":"Differential role of N-type calcium channel splice isoforms in pain","volume":"27","author":"Altier","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2013.06.057_bib0045","first-page":"CD006380","article-title":"Pharmacologic interventions for treating phantom limb pain","author":"Alviar","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neulet.2013.06.057_bib0050","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1146\/annurev-biochem-080411-121438","article-title":"The voltage-gated calcium channel functions as the molecular switch of synaptic transmission","volume":"82","author":"Atlas","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.neulet.2013.06.057_bib0055","first-page":"46","article-title":"Peptide drugs, overcoming the challenges, a growing business","volume":"24","author":"Ayoub","year":"2006","journal-title":"Chim. Oggi"},{"key":"10.1016\/j.neulet.2013.06.057_bib0060","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1001\/jama.280.21.1831","article-title":"Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial","volume":"280","author":"Backonja","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.neulet.2013.06.057_bib0065","first-page":"249","article-title":"Gabapentin for once-daily treatment of post-herpetic neuralgia: a review","volume":"7","author":"Beal","year":"2012","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.neulet.2013.06.057_bib0070","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0896-6273(03)00801-8","article-title":"Cell-specific alternative splicing increases calcium channel current density in the pain pathway","volume":"41","author":"Bell","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.neulet.2013.06.057_bib0075","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1523\/JNEUROSCI.23-17-06793.2003","article-title":"N-type calcium channel alpha1B subunit (Cav2.2) knock-out mice display hyperactivity and vigilance state differences","volume":"23","author":"Beuckmann","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2013.06.057_bib0080","first-page":"481","article-title":"Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study","volume":"27","author":"Bone","year":"2002","journal-title":"Reg. Anesth. Pain Med."},{"key":"10.1016\/j.neulet.2013.06.057_bib0085","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.bmcl.2013.03.114","article-title":"Modular, efficient synthesis of asymmetrically substituted piperazine scaffolds as potent calcium channel blockers","volume":"23","author":"Borzenko","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neulet.2013.06.057_bib0090","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1179\/joc.2002.14.2.214","article-title":"Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study","volume":"14","author":"Bosnjak","year":"2002","journal-title":"J. Chemother."},{"key":"10.1016\/j.neulet.2013.06.057_bib0095","series-title":"Dual regulation of voltage-and ligand-gated calcium channels by collapsin response mediator protein 2. Program in Medical Neuroscience Vol. Ph.D","first-page":"224","author":"Brittain","year":"2012"},{"key":"10.1016\/j.neulet.2013.06.057_bib0100","doi-asserted-by":"crossref","first-page":"37778","DOI":"10.1074\/jbc.M111.255455","article-title":"Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2)","volume":"286","author":"Brittain","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2013.06.057_bib0105","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.2345","article-title":"Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca(2)(+) channel complex","volume":"17","author":"Brittain","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.neulet.2013.06.057_bib0110","doi-asserted-by":"crossref","first-page":"31375","DOI":"10.1074\/jbc.M109.009951","article-title":"An atypical role for collapsin response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels","volume":"284","author":"Brittain","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2013.06.057_bib0115","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1016\/j.febslet.2012.09.022","article-title":"Cdk5-mediated phosphorylation of CRMP-2 enhances its interaction with CaV2.2","volume":"586","author":"Brittain","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neulet.2013.06.057_bib0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/1389201043489620","article-title":"From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future","volume":"5","author":"Bruckdorfer","year":"2004","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.neulet.2013.06.057_bib0125","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1113\/jphysiol.2010.204735","article-title":"Inhibition of synaptic transmission and G protein modulation by synthetic CaV2.2 Ca(2)+ channel peptides","volume":"589","author":"Bucci","year":"2011","journal-title":"J. Physiol."},{"key":"10.1016\/j.neulet.2013.06.057_bib0130","series-title":"Modulation of Presynaptic Calcium Channels","first-page":"223","article-title":"Use of synthetic ca2+ channel peptides to study presynaptic function","author":"Bucci","year":"2013"},{"key":"10.1016\/j.neulet.2013.06.057_bib0135","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/iub.383","article-title":"Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations","volume":"62","author":"Buchwald","year":"2010","journal-title":"IUBMB Life"},{"key":"10.1016\/j.neulet.2013.06.057_bib0140","unstructured":"W. Catterall, Z.-H. Sheng, Methods and compositions for screening for presynaptic calcium channel blockers, USA,WO 1996015149-83 1996."},{"key":"10.1016\/j.neulet.2013.06.057_bib0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.neulet.2010.08.085","article-title":"Signaling complexes of voltage-gated sodium and calcium channels","volume":"486","author":"Catterall","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neulet.2013.06.057_bib0150","doi-asserted-by":"crossref","first-page":"a003947","DOI":"10.1101\/cshperspect.a003947","article-title":"Voltage-gated calcium channels","volume":"3","author":"Catterall","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.neulet.2013.06.057_bib0155","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.neuron.2008.09.005","article-title":"Calcium channel regulation and presynaptic plasticity","volume":"59","author":"Catterall","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.neulet.2013.06.057_bib0160","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1242\/jcs.053280","article-title":"Regulation of N-type voltage-gated calcium (CaV2.2) channels and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons","volume":"23","author":"Chi","year":"2009","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.neulet.2013.06.057_bib0165","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2165\/00003495-200767040-00006","article-title":"Diabetic painful neuropathy: current and future treatment options","volume":"67","author":"Chong","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.neulet.2013.06.057_bib0170","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s00221-002-1217-3","article-title":"Localization of N-type Ca2+ channels in the rat spinal cord following chronic constrictive nerve injury","volume":"147","author":"Cizkova","year":"2002","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.neulet.2013.06.057_bib0175","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4161\/chan.2.2.6214","article-title":"Old proteins, developing roles: the regulation of calcium channels by synaptic proteins","volume":"2","author":"Davies","year":"2008","journal-title":"Channels (Austin)"},{"key":"10.1016\/j.neulet.2013.06.057_bib0180","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.brainresrev.2008.12.005","article-title":"Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment","volume":"60","author":"Dib-Hajj","year":"2009","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neulet.2013.06.057_bib0185","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1146\/annurev-neuro-060909-153234","article-title":"Sodium channels in normal and pathological pain","volume":"33","author":"Dib-Hajj","year":"2010","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neulet.2013.06.057_bib0190","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/13543784.13.7.875","article-title":"Intrathecal ziconotide for refractory pain","volume":"13","author":"Doggrell","year":"2004","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neulet.2013.06.057_bib0195","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nrn3317","article-title":"Calcium channel auxiliary alpha2delta and beta subunits: trafficking and one step beyond","volume":"13","author":"Dolphin","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neulet.2013.06.057_bib0200","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1600-0854.2007.00572.x","article-title":"A comprehensive model for the cellular uptake of cationic cell-penetrating peptides","volume":"8","author":"Duchardt","year":"2007","journal-title":"Traffic"},{"key":"10.1016\/j.neulet.2013.06.057_bib0205","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.cell.2009.09.025","article-title":"Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis","volume":"139","author":"Eroglu","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.neulet.2013.06.057_bib0210","doi-asserted-by":"crossref","first-page":"20171","DOI":"10.1074\/jbc.M300581200","article-title":"Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA","volume":"278","author":"Feng","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2013.06.057_bib0215","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1021\/bi035933x","article-title":"Pathway for polyarginine entry into mammalian cells","volume":"43","author":"Fuchs","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.neulet.2013.06.057_bib0220","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.drudis.2008.10.009","article-title":"Predicting druggable binding sites at the protein-protein interface","volume":"14","author":"Fuller","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neulet.2013.06.057_bib0225","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/jnnp.66.2.251","article-title":"Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial","volume":"66","author":"Gorson","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neulet.2013.06.057_bib0230","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1523\/JNEUROSCI.14-05-02800.1994","article-title":"Omega-conotoxin sensitivity and presynaptic inhibition of glutamatergic sensory neurotransmission in vitro","volume":"14","author":"Gruner","year":"1994","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2013.06.057_bib0235","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1097\/00001756-200108080-00027","article-title":"Differential nociceptive responses in mice lacking the alpha(1B) subunit of N-type Ca(2+) channels","volume":"12","author":"Hatakeyama","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.neulet.2013.06.057_bib0240","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nrd939","article-title":"Designing peptide receptor agonists and antagonists","volume":"1","author":"Hruby","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neulet.2013.06.057_bib0245","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1039\/b611791k","article-title":"Translating peptides into small molecules","volume":"2","author":"Hummel","year":"2006","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.neulet.2013.06.057_bib0250","series-title":"C. Institute of Medicine Report from the Committee on Advancing Pain Research, Education, Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research","year":"2011"},{"key":"10.1016\/j.neulet.2013.06.057_bib0255","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/jnc.12070","article-title":"Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide","volume":"124","author":"Ju","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2013.06.057_bib0260","article-title":"SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons","volume":"3","author":"Ju","year":"2013","journal-title":"Channels"},{"key":"10.1016\/j.neulet.2013.06.057_bib0265","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ccell.2007.10.006","article-title":"Pain management in the traumatic amputee","volume":"20","author":"Ketz","year":"2008","journal-title":"Crit. Care Nurs. Clin. North Am."},{"key":"10.1016\/j.neulet.2013.06.057_bib0270","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5483\/BMBRep.2007.40.3.302","article-title":"A proteomic screen for presynaptic terminal N-type calcium channel (CaV2.2) binding partners","volume":"40","author":"Khanna","year":"2007","journal-title":"J. Biochem. Mol. Biol."},{"key":"10.1016\/j.neulet.2013.06.057_bib0275","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1074\/jbc.M807179200","article-title":"Deletion of N-type Ca2+ channel Cav2.2 results in hyperaggressive behaviors in mice","volume":"284","author":"Kim","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2013.06.057_bib0280","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/mcne.2001.1013","article-title":"Altered nociceptive response in mice deficient in the alpha(1B) subunit of the voltage-dependent calcium channel","volume":"18","author":"Kim","year":"2001","journal-title":"Mol. Cell Neurosci."},{"key":"10.1016\/j.neulet.2013.06.057_bib0285","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-540-74805-2_3","article-title":"Presynaptic calcium channels: structure, regulators, and blockers","volume":"184","author":"Kisilevsky","year":"2008","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neulet.2013.06.057_bib0290","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1526-4637.2011.01118.x","article-title":"Intravenous injection of leconotide, an omega conotoxin: synergistic antihyperalgesic effects with morphine in a rat model of bone cancer pain","volume":"12","author":"Kolosov","year":"2011","journal-title":"Pain Med."},{"key":"10.1016\/j.neulet.2013.06.057_bib0295","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1526-4637.2009.00741.x","article-title":"CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain","volume":"11","author":"Kolosov","year":"2010","journal-title":"Pain Med."},{"key":"10.1016\/j.neulet.2013.06.057_bib0300","first-page":"10","article-title":"The future of peptide development in the pharmaceutical industry, pharmaufacturing","author":"Lax","year":"2010","journal-title":"Int. Pept. Rev."},{"key":"10.1016\/j.neulet.2013.06.057_bib0305","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00174856","article-title":"The effect of omega conotoxin GVIA, a peptide modulator of the N-type voltage sensitive calcium channels, on motor responses produced by activation of efferent and sensory nerves in mammalian smooth muscle","volume":"338","author":"Maggi","year":"1988","journal-title":"Naunyn-Schmiedebergs Archiv. Pharmacol."},{"key":"10.1016\/j.neulet.2013.06.057_bib0310","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pain.2010.10.007","article-title":"Increased risk of suicide under intrathecal ziconotide treatment? \u2013 A warning","volume":"152","author":"Maier","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.neulet.2013.06.057_bib0315","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1111\/j.1742-4658.2008.06601.x","article-title":"Crystal and solution structure, stability and post-translational modifications of collapsin response mediator protein 2","volume":"275","author":"Majava","year":"2008","journal-title":"FEBS J."},{"key":"10.1016\/j.neulet.2013.06.057_bib0320","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.coph.2008.06.002","article-title":"Discovering and improving novel peptide therapeutics","volume":"8","author":"McGregor","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neulet.2013.06.057_bib0325","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1034\/j.1399-3011.2000.00723.x","article-title":"Polyarginine enters cells more efficiently than other polycationic homopolymers","volume":"56","author":"Mitchell","year":"2000","journal-title":"J. Pept. Res."},{"key":"10.1016\/j.neulet.2013.06.057_bib0330","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0896-6273(00)80209-3","article-title":"Inhibition of neurotransmission by peptides containing the synaptic protein interaction site of N-type Ca2+ channels","volume":"17","author":"Mochida","year":"1996","journal-title":"Neuron"},{"key":"10.1016\/j.neulet.2013.06.057_bib0335","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","author":"Moore","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neulet.2013.06.057_bib0340","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/archinte.159.16.1931","article-title":"Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain","volume":"159","author":"Morello","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.neulet.2013.06.057_bib0345","doi-asserted-by":"crossref","first-page":"14950","DOI":"10.1073\/pnas.1005940107","article-title":"Quantitative proteomics of the Cav2 channel nano-environments in the mammalian brain","volume":"107","author":"Muller","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neulet.2013.06.057_bib0350","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/np200906s","article-title":"Natural products as sources of new drugs over the 30 years from 1981 to 2010","volume":"75","author":"Newman","year":"2012","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.neulet.2013.06.057_bib0355","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/00000542-200611000-00023","article-title":"A randomized study of the effects of gabapentin on postamputation pain","volume":"105","author":"Nikolajsen","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neulet.2013.06.057_bib0360","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.bmcl.2010.01.008","article-title":"Structure\u2013activity relationships of diphenylpiperazine N-type calcium channel inhibitors","volume":"20","author":"Pajouhesh","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neulet.2013.06.057_bib0365","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1016\/j.bmcl.2012.04.054","article-title":"Structure\u2013activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors","volume":"22","author":"Pajouhesh","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neulet.2013.06.057_bib0370","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1517\/13543784.2011.600686","article-title":"Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development","volume":"20","author":"Pexton","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neulet.2013.06.057_bib0375","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1744-8069-8-54","article-title":"CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy","volume":"8","author":"Piekarz","year":"2012","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neulet.2013.06.057_bib0380","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1358\/dot.2006.42.6.973534","article-title":"Ziconotide: a new option for refractory pain","volume":"42","author":"Prommer","year":"2006","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.neulet.2013.06.057_bib0385","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/104990910502200510","article-title":"Ziconotide: can we use it in palliative care?","volume":"22","author":"Prommer","year":"2005","journal-title":"Am. J. Hosp. Palliat. care"},{"key":"10.1016\/j.neulet.2013.06.057_bib0390","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1096\/fj.07-9012com","article-title":"CRMP3 is required for hippocampal CA1 dendritic organization and plasticity","volume":"22","author":"Quach","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.neulet.2013.06.057_bib0395","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1533-2500.2009.00303.x","article-title":"Intrathecal ziconotide for neuropathic pain: a review","volume":"9","author":"Rauck","year":"2009","journal-title":"Pain Pract."},{"key":"10.1016\/j.neulet.2013.06.057_bib0400","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1073\/pnas.93.14.7363","article-title":"Isoform-specific interaction of the alpha1A subunits of brain Ca2+ channels with the presynaptic proteins syntaxin and SNAP-25","volume":"93","author":"Rettig","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neulet.2013.06.057_bib0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/s13380-012-0002-4","article-title":"A Peptide uncoupling CRMP-2 from the presynaptic ca(2+) channel complex demonstrates efficacy in animal models of migraine and aids therapy-induced neuropathy","volume":"3","author":"Ripsch","year":"2012","journal-title":"Transl. Neurosci."},{"key":"10.1016\/j.neulet.2013.06.057_bib0410","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.280.21.1837","article-title":"Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial","volume":"280","author":"Rowbotham","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.neulet.2013.06.057_bib0415","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0885-3924(00)00243-8","article-title":"Gabapentin in phantom limb pain management in children and young adults: report of seven cases","volume":"21","author":"Rusy","year":"2001","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.neulet.2013.06.057_bib0420","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1093\/emboj\/20.10.2349","article-title":"Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel","volume":"20","author":"Saegusa","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.neulet.2013.06.057_bib0425","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(10)60354-6","article-title":"Ziconotide for treatment of severe chronic pain","volume":"375","author":"Schmidtko","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.neulet.2013.06.057_bib0430","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2174\/157340606778250216","article-title":"N-type calcium channel blockers: novel therapeutics for the treatment of pain","volume":"2","author":"Schroeder","year":"2006","journal-title":"Med. Chem."},{"key":"10.1016\/j.neulet.2013.06.057_bib0435","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0014-2999(02)02247-1","article-title":"Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat","volume":"451","author":"Scott","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neulet.2013.06.057_bib0440","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0304-3959(02)00255-5","article-title":"Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial","volume":"99","author":"Serpell","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.neulet.2013.06.057_bib0445","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1098\/rspb.1991.0061","article-title":"Mu-opioid-receptor-mediated inhibition of the N-type calcium-channel current","volume":"244","author":"Seward","year":"1991","journal-title":"Proc. Biol. Sci."},{"key":"10.1016\/j.neulet.2013.06.057_bib0450","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/379451a0","article-title":"Calcium-dependent interaction of N-type calcium channels with the synaptic core complex","volume":"379","author":"Sheng","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.neulet.2013.06.057_bib0455","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0896-6273(94)90417-0","article-title":"Identification of a syntaxin-binding site on N-type calcium channels","volume":"13","author":"Sheng","year":"1994","journal-title":"Neuron"},{"key":"10.1016\/j.neulet.2013.06.057_bib0460","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/10915810701582970","article-title":"Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class","volume":"26","author":"Skov","year":"2007","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.neulet.2013.06.057_bib0465","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0304-3959(01)00436-5","article-title":"The novel N-type calcium channel blocker AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices","volume":"96","author":"Smith","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.neulet.2013.06.057_bib0470","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1602\/neurorx.2.4.662","article-title":"Targeting chronic and neuropathic pain: the N-type calcium channel comes of age","volume":"2","author":"Snutch","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.neulet.2013.06.057_bib0475","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0166-2236(97)01091-6","article-title":"The calcium channel and the organization of the presynaptic transmitter release face","volume":"20","author":"Stanley","year":"1997","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neulet.2013.06.057_bib0480","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/138920109787048634","article-title":"Advances in peptide pharmaceuticals","volume":"10","author":"Stevenson","year":"2009","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.neulet.2013.06.057_bib0485","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1523\/JNEUROSCI.4497-06.2007","article-title":"Mice deficient in collapsin response mediator protein-1 exhibit impaired long-term potentiation and impaired spatial learning and memory","volume":"27","author":"Su","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neulet.2013.06.057_bib0490","article-title":"Characterization of the substituted N-triazole oxindole, TROX-1, a small molecule, state-dependent inhibitor of CaV2 calcium channels","author":"Swensen","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neulet.2013.06.057_bib0495","first-page":"147","article-title":"Treatment challenges and complications with ziconotide monotherapy in established pump patients","volume":"9","author":"Thompson","year":"2006","journal-title":"Pain Physician"},{"key":"10.1016\/j.neulet.2013.06.057_bib0500","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1476-5381.2011.01256.x","article-title":"T-type voltage-gated calcium channels as targets for the development of novel pain therapies","volume":"163","author":"Todorovic","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neulet.2013.06.057_bib0505","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/psc.968","article-title":"Live-cell analysis of cell penetration ability and toxicity of oligo-arginines","volume":"14","author":"Tunnemann","year":"2008","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.neulet.2013.06.057_bib0510","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4161\/chan.5.5.16473","article-title":"Signaling complexes of voltage-gated calcium channels","volume":"5","author":"Turner","year":"2011","journal-title":"Channels (Austin)"},{"key":"10.1016\/j.neulet.2013.06.057_bib0515","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3111\/13696998.2011.650773","article-title":"Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy","volume":"15","author":"Udall","year":"2012","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.neulet.2013.06.057_bib0520","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/papr.12008","article-title":"Identification of patients with painful diabetic peripheral neuropathy who have a favorable cost profile with pregabalin treatment","volume":"13","author":"Udall","year":"2013","journal-title":"Pain Pract."},{"key":"10.1016\/j.neulet.2013.06.057_bib0525","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","article-title":"Synthetic therapeutic peptides: science and market","volume":"15","author":"Vlieghe","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neulet.2013.06.057_bib0530","doi-asserted-by":"crossref","first-page":"9598","DOI":"10.1074\/jbc.M110.195909","article-title":"Beta-subunits promote the expression of Ca(V)2.2 channels by reducing their proteasomal degradation","volume":"286","author":"Waithe","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2013.06.057_bib0535","doi-asserted-by":"crossref","first-page":"13003","DOI":"10.1073\/pnas.97.24.13003","article-title":"The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters","volume":"97","author":"Wender","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neulet.2013.06.057_bib0540","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/0896-6273(92)90069-P","article-title":"Biochemical properties and subcellular distribution of an N-type calcium channel alpha 1 subunit","volume":"9","author":"Westenbroek","year":"1992","journal-title":"Neuron"},{"key":"10.1016\/j.neulet.2013.06.057_bib0545","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/14656566.9.9.1575","article-title":"Ziconotide: an update and review","volume":"9","author":"Williams","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.neulet.2013.06.057_bib0550","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4161\/chan.5.5.17363","article-title":"Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex","volume":"5","author":"Wilson","year":"2011","journal-title":"Channels (Austin)"},{"key":"10.1016\/j.neulet.2013.06.057_bib0555","doi-asserted-by":"crossref","first-page":"35065","DOI":"10.1074\/jbc.M112.378695","article-title":"Inhibition of transmitter release and attenuation of AIDS therapy-induced and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides","volume":"287","author":"Wilson","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2013.06.057_bib0560","first-page":"61","article-title":"Enzymatic barriers for Gi peptide and protein delivery","volume":"11","author":"Woodley","year":"1994","journal-title":"Crit. Rev. Ther. Drug"},{"key":"10.1016\/j.neulet.2013.06.057_bib0565","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jpain.2005.09.007","article-title":"Calcium channels as therapeutic targets in neuropathic pain","volume":"7","author":"Yaksh","year":"2006","journal-title":"J. Pain"},{"key":"10.1016\/j.neulet.2013.06.057_bib0570","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1016\/j.bmcl.2009.09.008","article-title":"Scaffold-based design and synthesis of potent N-type calcium channel blockers","volume":"19","author":"Zamponi","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neulet.2013.06.057_bib0575","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.brainresrev.2008.12.021","article-title":"Role of voltage-gated calcium channels in ascending pain pathways","volume":"60","author":"Zamponi","year":"2009","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neulet.2013.06.057_bib0580","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2147\/NDT.S3257","article-title":"New treatment options in the management of fibromyalgia: role of pregabalin","volume":"4","author":"Zareba","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.neulet.2013.06.057_bib0585","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4155\/fmc.09.23","article-title":"Manufacturing peptides as active pharmaceutical ingredients","volume":"1","author":"Zompra","year":"2009","journal-title":"Future Med. Chem."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394013006046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394013006046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T21:43:32Z","timestamp":1563313412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394013006046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":117,"alternative-id":["S0304394013006046"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2013.06.057","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2013.06.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}